| Summary of royalty and commercial payment receivable and contingent consideration activities |
The following table summarizes the royalty and commercial payment receivable activities under the cost recovery method during the six months ended June 30, 2025 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Acquisition of Royalty |
|
|
Receipt of Royalty |
|
|
|
|
|
|
Balance as of |
|
|
and Commercial |
|
|
and Commercial |
|
|
Balance as of |
|
|
|
January 1, 2025 |
|
|
Payment Receivables |
|
|
Payments |
|
|
June 30, 2025 |
Twist |
|
$ |
15,000 |
|
$ |
— |
|
$ |
— |
|
$ |
15,000 |
Daré (XACIATO) |
|
|
21,999 |
|
|
— |
|
|
(3) |
|
|
21,996 |
LadRx (MIPLYFFA) |
|
|
4,850 |
|
|
— |
|
|
(1,104) |
|
|
3,746 |
Palobiofarma |
|
|
10,000 |
|
|
— |
|
|
— |
|
|
10,000 |
Kuros |
|
|
4,500 |
|
|
— |
|
|
— |
|
|
4,500 |
Castle Creek |
|
|
— |
|
|
4,395 |
|
|
— |
|
|
4,395 |
Total |
|
$ |
56,349 |
|
$ |
4,395 |
|
$ |
(1,107) |
|
$ |
59,637 |
The following table summarizes the royalty and commercial payment receivable activities under the EIR method during the six months ended June 30, 2025 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchased |
|
Receipt of |
|
|
|
|
|
|
|
|
|
|
Receivables |
|
Royalty and |
|
Payment of |
|
|
|
|
|
Balance as of |
|
Under the |
|
Commercial |
|
Sales-Based |
|
|
Balance as of |
|
|
January 1, 2025 |
|
EIR Method |
|
Payments |
|
Milestone |
|
|
June 30, 2025 |
Affitech (VABYSMO) |
|
$ |
13,105 |
|
$ |
11,575 |
|
$ |
(11,145) |
|
$ |
3,000 |
|
$ |
16,535 |
Aptevo (IXINITY) |
|
|
6,628 |
|
|
502 |
|
|
(930) |
|
|
— |
|
|
6,200 |
Total |
|
$ |
19,733 |
|
$ |
12,077 |
|
$ |
(12,075) |
|
$ |
3,000 |
|
$ |
22,735 |
|
| Summary of income from purchased receivables under the cost recovery method and EIR method |
The following table summarizes income recognized from purchased receivables under the EIR method and cost recovery method during the three and six months ended June 30, 2025 and 2024 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
|
|
2025 |
|
2024 |
|
2025 |
|
2024 |
Affitech (VABYSMO) |
|
$ |
5,758 |
|
$ |
4,562 |
|
$ |
11,575 |
|
$ |
4,562 |
Aptevo (IXINITY) |
|
|
249 |
|
|
— |
|
|
502 |
|
|
— |
Total income from purchased receivables under the EIR method |
|
$ |
6,007 |
|
$ |
4,562 |
|
$ |
12,077 |
|
$ |
4,562 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Viracta (OJEMDA) |
|
$ |
1,715 |
|
$ |
870 |
|
$ |
7,240 |
|
$ |
870 |
Talphera |
|
|
28 |
|
|
— |
|
|
28 |
|
|
— |
Total income from purchased receivables under the cost recovery method |
|
$ |
1,743 |
|
$ |
870 |
|
$ |
7,268 |
|
$ |
870 |
|